Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Moderna, Inc. (NASDAQ:MRNA – Get Rating) Director Noubar Afeyan sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $130.37, for a total value of $1,303,700.00. Following the transaction, the director now owns 2,407,209 shares of the company’s stock, valued at approximately $313,827,837.33. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Noubar Afeyan also recently made the following trade(s):
- On Wednesday, September 14th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $134.00, for a total value of $1,340,000.00.
- On Wednesday, September 7th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $129.68, for a total value of $1,296,800.00.
- On Wednesday, August 17th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $165.24, for a total value of $1,652,400.00.
- On Wednesday, August 10th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $174.09, for a total value of $1,740,900.00.
- On Wednesday, August 3rd, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $167.99, for a total value of $1,679,900.00.
- On Wednesday, July 27th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $161.00, for a total value of $1,610,000.00.
- On Wednesday, July 20th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $167.00, for a total value of $1,670,000.00.
- On Wednesday, July 13th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $168.88, for a total value of $1,688,800.00.
- On Wednesday, July 6th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $154.85, for a total value of $1,548,500.00.
- On Wednesday, June 29th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $140.47, for a total value of $1,404,700.00.
Moderna Stock Down 0.5 %
MRNA stock traded down $0.68 on Friday, hitting $123.64. 3,846,404 shares of the company’s stock were exchanged, compared to its average volume of 6,482,984. Moderna, Inc. has a 12-month low of $115.61 and a 12-month high of $453.61. The firm has a 50 day moving average price of $151.78 and a two-hundred day moving average price of $150.72. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.71 and a current ratio of 1.99. The stock has a market cap of $49.18 billion, a P/E ratio of 3.77, a price-to-earnings-growth ratio of 0.73 and a beta of 1.69.
Moderna (NASDAQ:MRNA – Get Rating) last announced its earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping the consensus estimate of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The firm had revenue of $4.73 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the business earned $6.46 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, equities research analysts expect that Moderna, Inc. will post 26.41 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
MRNA has been the subject of a number of research analyst reports. Argus decreased their target price on Moderna from $180.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, September 14th. SVB Leerink lifted their target price on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research report on Monday, August 1st. Deutsche Bank Aktiengesellschaft raised Moderna from a “hold” rating to a “buy” rating and boosted their price target for the stock from $155.00 to $165.00 in a research report on Wednesday, September 7th. Finally, Morgan Stanley reduced their price target on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a research report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $211.08.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. Norges Bank purchased a new position in Moderna during the 4th quarter worth $773,229,000. Coatue Management LLC grew its stake in Moderna by 61.6% during the 1st quarter. Coatue Management LLC now owns 6,928,147 shares of the company’s stock valued at $1,193,443,000 after purchasing an additional 2,641,144 shares during the last quarter. Renaissance Technologies LLC grew its stake in Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares during the last quarter. Theleme Partners LLP grew its stake in Moderna by 26.2% during the 1st quarter. Theleme Partners LLP now owns 6,336,940 shares of the company’s stock valued at $1,091,601,000 after purchasing an additional 1,314,766 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Moderna by 3.7% during the 1st quarter. BlackRock Inc. now owns 28,671,935 shares of the company’s stock valued at $4,939,029,000 after purchasing an additional 1,010,462 shares during the last quarter. 60.76% of the stock is currently owned by hedge funds and other institutional investors.
About Moderna
(Get Rating)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
See Also
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Moderna, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn’t on the list.
While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
ETF portfolio manager, Dave Gilreath offers a perspective on “dividend achievers” and why these deserve a role in your portfolio
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
